What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
At TrimRx, the providers we partner with are available to help you navigate these challenges
To give you a quick recap: Semaglutide acts like GLP-1 Tirzepatide acts like GLP-1 and GIP Retatrutide acts like GLP-1, GIP and GCG That means that they may all bring on different weight loss results (which is what the research shows)
Hugon, F
It protects your skin from the radicals that can cause blemishes, dark spots, and skin pigmentation
described a patient with retrocaval MMNST who experienced decreased pain and disease stabilization with pembrolizumab prior to resection [35]